Search
Apixaban
go.drugbank.com/drugs/DB06605ApprovedInvestigationalIt is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FDA on December 28, 2012[L6043]. … Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic
Products: APIXABAN EG, ELIQUIS® 5 MGOrnidazole
go.drugbank.com/drugs/DB13026InvestigationalOrnidazole has been used in trials studying the prevention of Elective Colorectal Surgery.
Mixtures: ORNISASIN 500 MG/500 MG FILM TABLET, 10 ADET, ORNISASIN 500 MG/500 MG FILM TABLET, 20 ADETProducts: TIBERAL ROCHE AMPOLLAS 1G/6ML, TIBERAL ROCHE DE 500 MGCerivastatin
go.drugbank.com/drugs/DB00439ApprovedWithdrawnOn August 8, 2001 the U.S. … It has also been withdrawn from the Canadian market.[A669,L43942]
Mycophenolate mofetil
go.drugbank.com/drugs/DB00688ApprovedInvestigational[L7363] It is marketed by Roche Pharmaceuticals and was granted FDA approval for the prophylaxis of transplant rejection in 1995. … It demonstrates an increased bioavailability, a higher efficacy, and reduced gastrointestinal effects when compared to MPA.[A180826]
Synonyms: 2-morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoateProducts: Mycophenolatmofetil Accord 500 mg Pulver für ein Konzentrat zur Herstellung einer Infusionslösung, MYFENAX 500 MGFusidic acid
go.drugbank.com/drugs/DB02703ApprovedInvestigationalAn antibiotic isolated from the fermentation broth of Fusidium coccineum. (From Merck Index, 11th ed) It acts by inhibiting translocation during protein synthesis. … It is often used topically in creams and eyedrops but is available in systemic formulations including tablets and injections.
Mixtures: Fusicutan 20 mg/g + 1 mg/g Creme, Fucibet Lipid 20 mg/g + 1 mg/g CremeProducts: Natrium Fusidat Essential Pharma 500 mg-Pulver und Lösungsmittel für ein Konzentrat zur Herstellung einer Infusionslösung, BALAD TABLET 250 mgElacestrant
go.drugbank.com/drugs/DB06374ApprovedInvestigational[L44918,L44948] It received a similar approval in the EU in September 2023. … Elacestrant is a non-steroidal small molecule and an estrogen receptor (ER) antagonist.
Imlunestrant
go.drugbank.com/drugs/DB19043ApprovedInvestigationalprogression on at least one line of endocrine therapy. … [L54046] Imlunestrant works by antagonizing ER transcriptional activity and, by forming an unstable drug-receptor complex, promotes ER degradation via the ubiquitin-proteasome pathway.
Antihemophilic factor human
go.drugbank.com/drugs/DB13192ApprovedInvestigationalEndogenous Factor VIII is essential to the clotting process in the body due to its involvement in the clotting cascade where it is responsible for acting as a co-factor to Factor IX. … in the 1980s and 1990s [A31551, A32272].
Mixtures: BERIPLAST-P COMBI SET 1 ML TROMBİN ÇÖZELTİSİ VE 1 ML FİBRİNOJEN ÇÖZELTİSİ İÇEREN FİBRİN YAPIŞTIRICI, BERIPLAST-P COMBI SET 3 ML TROMBİN ÇÖZELTİSİ VE 1 ML FİBRİNOJEN ÇÖZELTİSİ İÇEREN FİBRİN YAPIŞTIRICIProducts: Profilate Heat Treated-wet Method Inj, FACTANE 500 IU/5 ML IV ENJ ICIN LIYOFIZE TOZ ICEREN FLAKON, 1 ADETCeftriaxone
go.drugbank.com/drugs/DB01212ApprovedInvestigational[A215582] It has a very long half-life compared to other cephalosporins and is high penetrable into the meninges[A215582], eyes[A215647], and inner ear[A215627].
Mixtures: CEFTRIAXONA 1000 MG + SULBACTAM 500 MGProducts: CEFTRIAXONE EG, ROCEPHIN VIAL 500 MG IVOritavancin
go.drugbank.com/drugs/DB04911ApprovedInvestigational[A39384,A193482,L8492] On March 12, 2021 the FDA approved Kimyrsa, a complete course of therapy in a single, 1 hour 1200 mg infusion. … [L32634] Orbactiv, the other FDA approved oritavancin product, is administered over a 3 hour infusion and contains a lower dose of 400 mg.